The Limited Times

Now you can see non-English news...

Covid-19: the French Medicines Agency has taken legal action on a contested trial of the IHU of Marseille

2023-06-08T13:52:21.550Z

Highlights: The national drug agency points to a study co-signed by Didier Raoult involving more than 30,000 patients treated with hydroxychloroquine. This study "can be qualified as RIPH (research involving the human person, Editor's note) category 1" and therefore "should have benefited from a favorable opinion of a committee for the protection of persons and an authorization from the ANSM", the agency says. Professor Raoult co-authored in March, with seven co-authors, most of whom still practice at the IHU, a "pre-print" of his study.


The national drug agency points to a study co-signed by Didier Raoult involving more than 30,000 patients treated with hydroxychloroquine.


The national drug agency (ANSM) announced Thursday that it had again seized the justice on dysfunctions of the IHU of Marseille in the Raoult era, this time on an unauthorized clinical trial on patients with Covid-19.

«

The ANSM has seized the justice again, "announced a spokeswoman to AFP, after analysis of a study on more than 30,000 Covid patients published, among others, by Didier Raoult. This study "can be qualified as RIPH (research involving the human person, Editor's note) category 1" and therefore "should have benefited from a favorable opinion of a committee for the protection of persons and an authorization from the ANSM".

'Potentially serious' effects of hydroxychloroquine

This study "can be qualified as RIPH (research involving the human person, Editor's note) category 1" and therefore "should have benefited from a favorable opinion of a committee for the protection of persons and an authorization from the ANSM".

Professor Raoult co-authored in March, with seven co-authors, most of whom still practice at the IHU, a "pre-print", that is to say a non-peer-reviewed version, of his study on Covid patients concluding that the administration of hydroxychloroquine (or ivermectin) reduced mortality.

" READ ALSO Ethics: the IHU of Didier Raoult brought to heel by the ANSM

In April, the Medicines Agency said the use of hydroxychloroquine "exposes patients to potential adverse effects that can be serious."

At the end of May, sixteen learned societies of medicine challenged the authorities on a lack of sanctions in the face of the "largest known 'wild' therapeutic trial ". Under pressure from the management of Marseille hospitals, Didier Raoult and the co-authors of the disputed "pre-print" finally decided to withdraw it, said last Friday the Marseille hospitals and the infectiologist.

Last Wednesday, the Minister of Health, François Braun, had brandished the threat of sanctions against these co-authors in the Senate, where he was questioned on "an inertia of the public authorities" in the face of the excesses of the IHU of Marseille under the Raoult era.

Source: lefigaro

All news articles on 2023-06-08

You may like

Trends 24h

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.